Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal

被引：15
作者：
Sallah, S
Isaksen, M
Seremetis, S
Rojkjaer, LP
机构：
[1] Novo Nordisk AS, Biopharm, DK-2880 Bagsvaerd, Denmark
[2] Novo Nordisk AS, Int Prod Safety, DK-2820 Gentofte, Denmark
[3] Novo Nordisk AS, Med Dev, DK-2880 Bagsvaerd, Denmark
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2005年 / 3卷 / 04期
关键词：
D O I：
10.1111/j.1538-7836.2005.01254.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：820 / 822
页数：3
相关论文
共 18 条
[1]   Renal failure associated with the use of celecoxib and rofecoxib [J].
Ahmad, SR ;
Kortepeter, C ;
Brinker, A ;
Chen, M ;
Beitz, J .
DRUG SAFETY, 2002, 25 (07) :537-544
[2]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708
[3]   Mechanism of factor VIIa-dependent coagulation in hemophilia blood [J].
Butenas, S ;
Brummel, KE ;
Branda, RF ;
Paradis, SG ;
Mann, KG .
BLOOD, 2002, 99 (03) :923-930
[4]   Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials [J].
Caldwell, SH ;
Chang, C ;
Macik, BG .
HEPATOLOGY, 2004, 39 (03) :592-598
[5]   Postmarketing surveillance - Lack of vigilance, lack of trust [J].
Fontanarosa, PB ;
Rennie, D ;
DeAngelis, CD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2647-2650
[6]   Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets [J].
Gabriel, DA ;
Li, X ;
Monroe, DM ;
Roberts, HR .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1816-1822
[7]   Thrombosis and recombinant factor VIIa [J].
Hay, CRM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1698-1699
[8]   EFFICACY AND SAFETY OF VAPOR-HEATED ANTI-INHIBITOR COAGULANT COMPLEX IN HEMOPHILIA PATIENTS [J].
HILGARTNER, M ;
ALEDORT, L ;
ANDES, A ;
GILL, J .
TRANSFUSION, 1990, 30 (07) :626-630
[9]   High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system [J].
Kjalke, M ;
Ezban, M ;
Monroe, DM ;
Hoffman, M ;
Roberts, HR ;
Hedner, U .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (01) :114-120
[10]   A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [J].
Labenz, J ;
Petersen, KU ;
Rösch, W ;
Koelz, HR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) :1015-1019
12